MFG
SNDX icon

Merit Financial Group’s Syndax Pharmaceuticals SNDX Stock Holding History

Merit Financial Group’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-10,954
Closed -$256K – 2438
2026
Q1 		$256K Buy
+10,954
New +$238K ﹤0.01% 1760

Other funds holding SNDX

HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
TE
Tema ETFs New York $3.09B AUM 72.72% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
DT
Diversified Trust Memphis, Tennessee $6.24B AUM 28.78% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
HCA
Harbour Capital Advisors Tysons Corner, Virginia $549M AUM 54.99% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
PR
PSP Research Newtown Square, Pennsylvania $188M AUM
PRTG
Post Resch Tallon Group Pittsford, New York $145M AUM 25.19% 1-Year Est. Return

Merit Financial Group's SNDX Position: Q2 2026 in Review

Merit Financial Group sold out of Syndax Pharmaceuticals (SNDX) in Q2 2026, closing a stake of 10,954 shares — an estimated $256K sold.

Merit Financial Group first reported a position in SNDX in Q1 2026 and held it in 1 quarter. The position peaked at $256K in Q1 2026. 23 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.

  • Merit Financial Group reported no remaining Syndax Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Merit Financial Group sold 10,954 Syndax Pharmaceuticals shares in Q2 2026, an estimated $256K.
  • Merit Financial Group first reported a position in Syndax Pharmaceuticals in Q1 2026 and held it in 1 quarter.
  • Merit Financial Group's Syndax Pharmaceuticals position peaked at $256K in Q1 2026.
  • 23 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.

Based on Merit Financial Group's 13F filing for Q2 2026, filed 17 Jul 2026.